Integral Diagnostics Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Integral Diagnostics wird ein jährliches Gewinn- und Umsatzwachstum von 82.9% bzw. 5.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 100% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.9% betragen.

Wichtige Informationen

77.0%

Wachstumsrate der Gewinne

91.7%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	25.3%
Wachstumsrate der Einnahmen	6.3%
Zukünftige Eigenkapitalrendite	12.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	27 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

CHIA:IDX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2027	576	40	94	117	5
6/30/2026	532	30	57	86	10
6/30/2025	504	22	52	77	9
6/30/2024	470	-61	42	66	N/A
3/31/2024	463	-59	29	62	N/A
12/31/2023	456	-58	20	62	N/A
9/30/2023	449	-16	24	67	N/A
6/30/2023	441	25	23	67	N/A
3/31/2023	418	23	20	56	N/A
12/31/2022	395	21	17	45	N/A
9/30/2022	378	18	13	41	N/A
6/30/2022	361	15	9	37	N/A
3/31/2022	361	18	14	41	N/A
12/31/2021	360	22	18	44	N/A
9/30/2021	356	26	34	57	N/A
6/30/2021	351	31	49	70	N/A
3/31/2021	333	32	54	73	N/A
12/31/2020	315	32	59	76	N/A
9/30/2020	295	28	44	65	N/A
6/30/2020	276	23	28	54	N/A
3/31/2020	263	22	19	47	N/A
12/31/2019	250	21	9	39	N/A
9/30/2019	241	21	12	37	N/A
6/30/2019	232	21	15	34	N/A
3/31/2019	222	19	14	30	N/A
12/31/2018	211	17	13	26	N/A
9/30/2018	200	16	14	26	N/A
6/30/2018	189	15	15	27	N/A
3/31/2018	187	15	N/A	27	N/A
12/31/2017	185	15	N/A	27	N/A
9/30/2017	182	15	N/A	25	N/A
6/30/2017	180	15	N/A	23	N/A
3/31/2017	177	16	N/A	26	N/A
12/31/2016	175	16	N/A	30	N/A
9/30/2016	171	14	N/A	27	N/A
6/30/2016	168	11	N/A	24	N/A
3/31/2016	165	11	N/A	22	N/A
12/31/2015	162	11	N/A	20	N/A
9/30/2015	157	8	N/A	18	N/A
6/30/2015	151	5	N/A	17	N/A
6/30/2014	4	3	N/A	4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IDX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.3%).

Ertrag vs. Markt: IDX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: IDX wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: IDXDie Einnahmen des Unternehmens (5.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (5.4% pro Jahr).

Hohe Wachstumseinnahmen: IDXDie Einnahmen des Unternehmens (5.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: IDXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.9%).

Integral Diagnostics Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Full year 2024 earnings released: AU$0.26 loss per share (vs AU$0.11 profit in FY 2023)

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

First half dividend of AU$0.025 announced

First half 2024 earnings released: AU$0.29 loss per share (vs AU$0.069 profit in 1H 2023)

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Investor sentiment deteriorates as stock falls 27%

Integral Diagnostics Limited Appoints Toby Hall as Director

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Full year 2023 earnings released: EPS: AU$0.11 (vs AU$0.07 in FY 2022)

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Integral Diagnostics Limited Announces Board Changes

Upcoming dividend of AU$0.025 per share at 2.0% yield

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023

Now 21% undervalued

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

Independent Non-Executive Director recently bought AU$114k worth of stock

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended June 30, 2022, Payable on October 5, 2022

Full year 2022 earnings released

Investor sentiment improved over the past week

Integral Diagnostics Limited Announces Appointment of Andrew Fay as an Independent Non-Executive Director

Now 21% undervalued after recent price drop

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Integral Diagnostics Limited (ASX:IDX) ) agreed to acquire Exact Radiology Pty Ltd for NZD 33.3 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Exact Radiology Pty Ltd for approximately AUD 39 million.

Executive Director recently bought AU$70k worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Integral Diagnostics Limited Announces the Distribution for the Six Months Ended December 31, 2021, Payable on April 4, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.12 in FY 2020)

Executive Director has left the company

First half 2021 earnings released: EPS AU$0.10 (vs AU$0.062 in 1H 2020)

Revenue beats expectations

Integral Diagnostics Limited Announces Retirement of Dr. Chien Ho as Executive Director, Effective on March 1, 2021

Integral Diagnostics Limited to Report First Half, 2021 Results on Feb 22, 2021

New 90-day high: AU$4.48

New 90-day high: AU$4.42

Executive Director recently sold AU$266k worth of stock

Executive Director recently sold AU$123k worth of stock

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Ascot Radiology Limited for NZD 54 million.

Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Ascot Radiology Limited.

New 90-day high - AU$4.30

Earnings released

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken